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Abstract
Background: Antigen desensitization through oral tolerance is becoming an increasingly attractive treatment
option for allergic diseases. However, the mechanism(s) by which tolerization is achieved remain poorly defined. In
this study we endeavored to induce oral tolerance to cockroach allergen (CRA: a complex mixture of insect
components) in order to ameliorate asthma-like, allergic pulmonary inflammation.
Methods: We compared the pulmonary inflammation of mice which had received four CRA feedings prior to
intratracheal allergen sensitization and challenge to mice fed PBS on the same time course. Respiratory parameters
were assessed by whole body unrestrained plethysmography and mechanical ventilation with forced oscillation.
Bronchoalveolar lavage fluid (BAL) and lung homogenate (LH) were assessed for cytokines and chemokines by
ELISA. BAL inflammatory cells were also collected and examined by light microscopy.
Results: CRA feeding prior to allergen sensitization and challenge led to a significant improvement in respiratory
health. Airways hyperreactivity measured indirectly via enhanced pause (Penh) was meaningfully reduced in the
CRA-fed mice compared to the PBS fed mice (2.3 ± 0.4 vs 3.9 ± 0.6; p = 0.03). Directly measured airways resistance
confirmed this trend when comparing the CRA-fed to the PBS-fed animals (2.97 ± 0.98 vs 4.95 ± 1.41). This effect
was not due to reduced traditional inflammatory cell chemotactic factors, Th2 or other cytokines and chemokines.
The mechanism of improved respiratory health in the tolerized mice was due to significantly reduced eosinophil
numbers in the bronchoalveolar lavage fluid (43300 ± 11445 vs 158786 ± 38908; p = 0.007) and eosinophil specific
peroxidase activity in the lung homogenate (0.59 ± 0.13 vs 1.19 ± 0.19; p = 0.017). The decreased eosinophilia was
likely the result of increased IL-10 in the lung homogenate of the tolerized mice (6320 ± 354 ng/mL vs 5190 ± 404
ng/mL, p = 0.02).
Conclusion: Our results show that oral tolerization to CRA can improve the respiratory health of experimental mice
in a CRA-induced model of asthma-like pulmonary inflammation by reducing pulmonary eosinophilia.
Background
Asthma is a significant chronic health problem in the U.
S. and other developed nations. It accounts for millions
of hospitalizations and thousands of deaths per year.
The incidence of this burdensome ailment has increased
by 50% every ten years raising the prevalence in the U.S.
to 26.7 million in 1997 [1,2].
A significant disparity in new asthma diagnoses has
been noted between urban and suburban/rural children.
Urban children suffer a significantly higher incidence of
asthma than their non city-dwelling counterparts [1].
This effect has been attributed to differences in expo-
sure to sensitizing allergens present in the environment.
Namely, it is theorized that an allergen(s) present at
higher concentration, or in a unique combination in
urban environments is the principal aggravating factor.
Suspected allergens include feline, canine, murine, dust
mite and cockroach allergen and pollutants such as die-
sel particulates.
A landmark paper published in 1997 identified a link
between asthma incidence in urban children and antigens
derived from the ubiquitous pest Blattella germanica, the
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any medium, provided the original work is properly cited.German cockroach [3]. This link was further investigated
in 1998 by the development of the first cockroach allergen
induced model of asthma [4]. Publications from this lab
have shown that aqueous house dust extract from the
kitchens of severely asthmatic, urban children can induce
allergic asthma-like symptoms in mice. Moreover, the
most potent and abundant allergens identified in the dust
extract were proteins of the German cockroach [5]. Thus,
the study of cockroach allergen as an inducer of asthma in
mice and humans is a rational first step in untangling the
complex web of environmental exposure and allergic
asthma.
Despite the alarming increase in prevalence and inci-
dence of asthma in recent times, treatments have evolved
slowly. Current standards of care include a long lasting
anti-inflammatory agent such as an inhaled glucocorti-
coid or long acting b2 adrenergic agonist, combined with
a short acting b2 agonist rescue inhaler and or epinephr-
ine injections. Other effective agents include anti-IgE
monoclonal antibodies, leukotriene receptor antagonists,
mast cell degranulation inhibitors, antihistamines and
cholinergic antagonists [1,6,7]. These treatments focus
on alleviating the symptoms of the disease rather than
addressing the cause. Specifically, they manipulate events
occurring downstream of the aggravating stimulus to
diminish certain aspects of the response. While these
drugs are very effective at decreasing exacerbations
and halting attacks, they tend to lose effectiveness over
time. Asthma progresses because chronic, inflammation-
induced lung remodeling coupled with drug desensitiza-
tion, allow the disease to become more severe and
recalcitrant to treatment over time.
Allergen desensitization is thus a highly attractive
option for the treatment of allergic-type inflammatory
diseases. This form of treatment has a significant advan-
tage over standard therapeutic agents in that it
addresses the fundamental cause of asthma rather than
modifying downstream mediators. In addition allergen
desensitization has the advantage of being tailored to
the individual patient. A skin hypersensitivity panel can
be performed for a wide array of potential allergens in
order to identify the causative agent(s). Thus, the desen-
sitization regimen can be narrowly focused on the most
likely causative allergens, offering symptomatic relief
based on rational and specific treatment targeted to the
inciting allergens(s).
Current desensitization procedures deliver increasing
titers of the putative allergen subcutaneously over a per-
iod of weeks. The patient must travel to their physi-
cian’s office and remain in the clinic for 30 minutes
after the injection in case a life-threatening reaction
occurs. In addition, the administering health profes-
sional must be specially trained and have the capacity
to treat severe anaphylaxis [8,9]. These factors make
current desensitization procedures relatively costly and
inconvenient for both the patient and the care provider.
Sublingual/oral allergen desensitization is starting to
gain wider interest and acceptance [10,11] with signifi-
cant advantages over subcutaneous desensitization.
Chief among these is the lower potential for anaphylaxis.
The patient is monitored for severe reactions only after
the first dose; subsequently, he/she can self-administer
treatment in their own home. This vastly increases com-
pliance as there is very little disruption of the patient’s
daily schedule. This is especially true for asthmatic chil-
dren in whom compliance is a significant issue. There-
fore, oral desensitization is an ideal candidate for the
treatment of allergic type asthma.
Although oral tolerance is gaining wider acceptance,
the mechanism of how this occurs has not been deter-
mined. We designed studies to examine whether oral
tolerance would effectively relieve asthma-like pulmon-
ary inflammation in response to cockroach allergens,
and determine the mechanism(s) of why oral tolerance
is effective.
Methods
Experimental model
We used exclusively female HSD-ICR mice at 18-20
grams. (Harlan Sprague Dawley Inc., Frederick, MD).
All data represent the combination of 3 replicates
except for direct airways resistance measurement
which is the combination of 2 replicates. All experi-
ments were reviewed and approved by the Boston
University School of Medicine Institutional Animal
Care and Use Committee.
Allergen feeding
Oral exposure to allergens was performed by gavage.
Briefly, a solution containing 16 ug of combined Blag1
and Blag2 was prepared in 100 ul of PBS. Mice were
lightly anesthetized with isoflurane and the solution
delivered directly to the stomach by means of a metal
gavage needle. Control mice received 100 ul of PBS by
the same method. Feeding was performed daily for
4d a y s .T h em i c ew e r eg i v e na3d a yr e s tp e r i o db e f o r e
the allergen sensitization protocol. For allergen specifi-
city ovalbumin (OVA) was given on the same schedule
and volume as those described above. The OVA solu-
tion was adjusted to provide the same total protein con-
centration as the CRA mixture, 7.35 mg/mL. Following
the OVA tolerization period, the mice received CRA
immunization and 2 CRA challenges along the same
schedule as the CRA tolerized animals.
Allergen sensitization
Cockroach antigen (CRA) was purchased from Greer
Laboratories (Lenoir, NC) as a lyophilized whole body
Vaickus et al. Respiratory Research 2010, 11:160
http://respiratory-research.com/content/11/1/160
Page 2 of 11extract of the German cockroach Blattella germanica.
The CRA was reconstituted in sterile PBS and the con-
centration of components Blag1 and Blag2 were assayed
by ELISA. The concentration of the solution was
adjusted so that 50 ul contained 8 ug of combined Blag1
and Blag2. The immunization (day 0) and 2 challenges
(days 14 and 21) were delivered intratracheally by direct
pharyngeal delivery which is subsequently inhaled [12].
Briefly, the mouse was suspended by its front incisors
on an incline board, its tongue was gently pulled for-
ward and the CRA solution was placed at the back of
the pharynx in two 25 ul aliquots for aspiration. The
i m m u n i z a t i o nd o s ew a sa1 : 2o ft h es t o c ks o l u t i o na n d
the challenges were a 1:4 containing 4 ug and 2 ug com-
bined Blag1 and Blag2 respectively. The naïve mice
received no CRA challenges. The 0 Hr mice were admi-
nistered 2 intratracheal challenges of CRA and were
assayed and sacrificed at the time they would have
received their final allergen challenge, i.e. they did not
receive the third challenge. The 1.5 Hr and 24 Hr mice
were given the full set of 3 challenges and were assayed
and sacrificed at 1.5 and 24 hours post final challenge
respectively.
Respiratory measurements
Mice were placed in unrestrained whole body plethys-
mograph chambers at the same time of day and exposed
to a 2 minute aerosolization of PBS, 25 mg/mL or
50 mg/mL methacholine followed by a 5 minute record-
ing period [13,14]. The mice were first allowed to
explore the chambers with normal grooming behavior
indicating that the mice had become acclimated. Direct
resistance measurements were made on a flexivent
instrument (ScireQ, Montreal, QC, Canada). Briefly,
mice were anesthetized with pentobarbital, and the tra-
chea was directly cannulated through a small incision.
The mice were placed on the mechanical ventilator and
then paralyzed with pancuronium bromide. A nebulizer
attached to the instrument delivered PBS, and metha-
choline challenges at 25 and 50 mg/mL while airways
resistance was measured.
Sacrifice and Data Collection
T h em i c ew e r ea n e s t h e t i z e dw i t hi n t r p e r i t o n e a lk e t a -
mine/xylazine and then sacrificed by exsanguination and
cervical dislocation. The trachea was opened and cannu-
lated with a length of flexible tubing and the lungs were
lavaged with 2 mL of warm HBSS in 250 ul aliquots.
The left lung was removed and fixed in 70% ethanol for
histology. The right lung was placed into ice cold Com-
plete Protease Inhibitor Cocktail (Roche Chemicals,
Switzerland). The right lungs are then homogenized, the
homogenate centrifuged at 10,000 G for 15 minutes and
the supernatant removed for cytokine analysis. The
cellular components of the whole lung homogenate
were then resuspended in 0.5% cetyltrimethylammonium
chloride (CTAC) and sonicated to release the contents
of the eosinophilic granules. The supernatant of this
mixture was collected and assessed for peroxidase activ-
ity (EPO). The lavage fluid was centrifuged at 600 G for
5 minutes and the supernatant was removed. The cell
pellet was resuspended in 200 ul of RPMI, the red cells
lysed and counted on Coulter particle counter (Beckman
Coulter, Fullerton CA). The cells were then adhered to a
slide and counted at 100 × magnification. The absolute
cell counts per BAL sample were calculated for total
white cells, neutrophils, macrophages, eosinophils and
lymphocytes. Blood samples were taken from each
mouse at exsanguination for cell counting on a Hemavet
(Drew Scientific, Dallas, TX). Cell counts were expressed
as the absolute number of a particular cell per 20 ul
blood sample.
Cytokine and chemokine analysis
Cytokines and chemokines were measured using sand-
wich ELISA [15]. Briefly, Nunc (Rochester, NY) plates
were coated overnight at 4C with anti-cytokine antibo-
dies, the plates were blocked, samples were incubated on
plates for 2 hours at room temperature, a biotinylated
secondary antibody was used to detect captured cyto-
kines and chemokines following incubation with strepavi-
din conjugated horse radish peroxidase (SA-HRP) and a
colorimetric reaction. BAL samples were diluted 1:2, lung
homogenate samples were diluted 1:5 and standards con-
tained an equal concentration of pooled naïve lung
homogenate. Plates were read with a PowerWaveX plate
reader (Bio-Tek Instruments, Hopkinton, MA).
Statistics
Statistical comparisons were performed by two-tailed
t-test in Graphpad Prism 4.0 (La Jolla, CA). Power ana-
lysis was performed using freeware tools on http://www.
biomath.info/. The coefficient of variance was calculated
as the ratio of the standard deviation and the mean of
each data set or CV = standard deviation/mean.
Results
Respiratory Parameters
Initially, we examined the respiratory parameters in CRA-
fed (tolerized) and PBS-fed mice following allergen sensiti-
zation and 2 challenges. We compared respiratory data in
response to 50 mg/mL of methacholine (Mch) because
this dose provided a maximal response. The first para-
meter we analyzed was enhanced pause (Penh). Penh is a
dimensionless composite parameter which can be used to
screen experimental animals for airways hyperreactivity to
Mch and obstruction [16-18]. Changes in Penh can be
caused by any factor which alters the caliber of conducting
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tion and luminal obstruction with mucus.
The Penh values of the CRA Fed mice were found to
be significantly lower than that of the PBS Fed animals
(Figure 1A). Because the reporting of plethysmograph
data in isolation is controversial, this result was further
verified by employing a forced oscillation device (FO)
to directly assess airways resistance [19-21]. In these
FO experiments, we compared the airways resistance
of the CRA or PBS fed mice in response to 25 mg/mL
of methacholine because this represented the plateau
of airways hyper-responsiveness. The CRA fed mice
confirmed the trend towards decreased airways resis-
tance which was not significant (Figure 1A). Power
analysis revealed that 21 experimental animals per
group would be needed to verify this difference in a
statistically significant manner. This value is very close
to the 19 animals per group which were needed to
identify the difference using Penh. Finally, the directly
measured resistance values in CRA and PBS fed mice
were compared with the analogous Penh values using a
ranked Pearson correlation. This analysis revealed a
93% correlation between resistance and Penh in the
CRA fed mice and an 81% correlation in the PBS fed
animals.
Next we examined a host of other respiratory para-
meters which we have found to be correlated with the
respiratory health of mice in our model of asthma.
First we examined minute ventilation (MV). The min-
ute ventilation of the CRA fed mice was significantly
higher than that of the PBS fed animals (Figure 1B).
Maintenance of an elevated MV in times pulmonary
distress is associated with superior respiratory health
[22-24]. Namely, when lung disease is more severe,
acute exacerbations cause involuntary decreases in
MV. To determine the etiology of this difference we
examined the components of MV, respiratory rate (RR)
and tidal volume (TV). Respiratory rate was signifi-
cantly higher in the CRA fed mice but there was no
difference in TV (Figure 1C, D). This indicates that the
low MV in the PBS fed mice was due principally to a
depressed RR.
Figure 1 Oral tolerance improves pulmonary respiratory parameters. Penh and resistance (A) were measured in CRA fed and PBS fed mice
4 hours after final CRA challenge. Penh was recorded at the plateau of airways hyperresponsiveness, 50 mg/mL for 5 minutes for Penh and 25
mg/mL for 10 minutes for resistance. Minute ventilation (B), respiratory rate (C) and tidal volume (D) were measured in CRA fed and PBS fed
mice 4 hours after final CRA challenge. Data were recorded for 5 minutes in response to 50 mg/mL of methacholine. Each value is the mean ±
SEM for n = 18 (Figure 1A Penh, 1B, 1C, 1D) and n = 8 (Figure 1A Resistance). * = p < 0.05 comparing CRA fed to PBS fed mice.
Vaickus et al. Respiratory Research 2010, 11:160
http://respiratory-research.com/content/11/1/160
Page 4 of 11Next we compared the time of inspiration (Ti) and
expiration (Te) of the CRA or PBS fed mice. The orally
tolerized mice displayed significantly lower Ti and Te
when compared to the PBS fed animals (Figure 2A, B).
Increased Ti and especially Te is associated with airways
obstruction in inflammatory processes [25-28]. Finally
we examined the peak inspiratory (PIF) and expiratory
(PEF) flow rates which indicate the forcefulness of the
inspiratory and expiratory cycles respectively. Serial
measurements of PEF (peak flow) are often used to eval-
uate the effectiveness of asthma control regimens [25].
PIF was significantly depressed in the PBS fed animals
as compared to the CRA fed mice while PEF showed no
significant differences between the groups (Figure 2C,
D). These data, considered together suggest that the
CRA Fed mice are in a superior state of respiratory
health and were better able to compensate upon expo-
sure to methacholine (by increasing RR, and PIF and
maintaining low Ti and Te) in order to maintain an ele-
vated minute ventilation.
Pulmonary Inflammation
To determine whether this improvement in respiratory
health was due to inhibition of inflammatory cell
recruitment we analyzed the inflammatory cells present
in the bronchoalveolar lavage fluid (BAL) of the experi-
mental mice. First we examined the levels of neutro-
phils, macrophages and lymphocytes. Neutrophils are
potent inflammatory mediators in asthma and typically
arrive to sites of inflammation in a rapid fashion [29,30].
Macrophages are the only inflammatory cells typically
present in the lungs and serve as immune surveillance
[31]. Finally, lymphocytes are key components of the
adaptive immune system and T-regs are thought to be
important in the execution of immune tolerance to
ingested antigen [32-34]. However, the counts of neutro-
phils, lymphocytes and monocytes were not significantly
different in the lavage fluid of the CRA fed mice as
compared to the PBS fed mice (Figure 3A-C).
Lung eosinophilia is a hallmark of severe asthma.
These cells respond to many chemotactic factors
Figure 2 Oral tolerance improves inspiratory and expiratory parameters. Time of inspiration (A), time of expiration (B), peak inspiratory flow
rate (C) and Peak expiratory flow rate (D) were measured in CRA fed and PBS fed mice 4 hours after final CRA challenge. Data were recorded for
5 minutes in response to 50 mg/mL of methacholine. Each value is the mean ± SEM for n = 18. * = p < 0.05 and ** = p < 0.01 comparing CRA
fed to PBS fed mice.
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cells and macrophages among others) and the Th2 cyto-
kines IL-4, 5 and 13 (released primarily from T cells)
[35-37]. Eosinophil counts were significantly depressed
in the CRA fed group (Figure 4A,C,D). We verified the
diminished presence of eosinophils by measuring the
eosinophil specific peroxidase (EPO) activity of the lung
homogenate and found that it was significantly
decreased in the CRA fed animals (Figure 4B). Finally,
we measured the levels of circulating eosinophils in the
blood using a Hemavet and found no statistically signifi-
cant difference between the CRA-fed and PBS-fed
groups of mice (Figure 4E) Blood eosinophil numbers
are displayed as the absolute number of cells per 20 ul
blood sample. Each value is the mean ± SEM for n =
18. ** = p < 0.01 comparing CRA fed to PBS fed mice.
We verified that the tolerization effect was antigen
specific through OVA experiments. Mice were tolerized
to OVA and then sensitized and challenged with CRA.
There was no difference in the airways hyperreactivity
Figure 3 Bronchoalveolar lavage (BAL) cellular constituents. BAL neutrophils (A), macrophages (B) and lymphocytes (C) in CRA fed and PBS
fed mice harvested 4 hours after final CRA challenge. There was no change in the number of these cells in the BAL. Cell counts were expressed
as the absolute number of cells collected in each sample. Each value is the mean ± SEM for n = 18.
Figure 4 Pulmonary and blood eosinophil recruitment. Bronchoalveolar lavage eosinophils (A) and lung homogenate eosinophil specific
peroxidase (EPO) activity (B) were measured in CRA fed and PBS fed mice 4 hours after final CRA challenge. EPO was assessed in the lung
homogenate following lavage to collect cells. Representative cytospin images from CRA fed (C) and PBS fed (D) mice stained with H+E at 100×.
The circulating blood levels of eosinophils (E) were assessed in CRA fed and PBS fed mice 4 hours after final challenge using a Hemavet. Each
value is the mean ± SEM for n = 18. ** = p < 0.01 comparing CRA fed to PBS fed mice.
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phils or lung homogenate EPO levels (Figure 5A-C).
In order to determine a mechanism of depressed
eosinophil recruitment in the CRA fed mice we exam-
ined a number of cytokines and chemokines in the
bronchoalveolar lavage fluid (BAL) and lung homoge-
nate supernatant (LH) (Table 1). The most obvious
candidates, eotaxins 1 and 2 did not differ between the
two experimental groups. Additionally, we found no
significant differences in any of the Th2 cytokines
(IL-4, IL-5 and IL-13) or in any of the mediators often
associated with airways hyperreactivity such as TNF-a
and IFN. To see if the depressed eosinophil recruit-
ment could be related to antibody production, we mea-
sured serum IgG and IgE and found no significant
difference between CRA and PBS fed mice. Addition-
ally, histological analysis of whole lung sections with
PAS stain revealed no difference in airways mucus
levels between the experimental groups (Figure 6A-C).
Finally, we examined IL-10 levels in the BAL and LH
as this cytokine is known to inhibit eosinophil recruit-
ment to the lung [38,39]. The BAL showed equivalent
levels of IL-10 between the CRA and PBS fed mice.
However, the lung homogenate supernatant of the CRA
fed mice contained significantly elevated levels of IL-10
compared to the PBS fed animals (Figure 7). Addition-
ally, the serum levels of IL-10 were below detection
limit in both groups of mice (data not shown).
Discussion
A number of research groups have reported ameliora-
tion of experimental allergic and autoimmune diseases
through the establishment of oral tolerance [40-42].
Most of these studies employed well defined solitary
antigens such as OVA in order to isolate the desired
response without excessive background interference.
Our current work differed from previous approaches in
that it employed a complex allergen mixture containing
the defatted whole body extract of German cockroaches.
This mixture contains the complete corporeal proteins
of the cockroach, as well as a host of bioactive enzymes
and the innate immune stimulants chitin and LPS.
These experiments represent a broader approach to
allergen desensitization. Namely, this study sought to
tolerize experimental animals to the whole host of cock-
roach derived products which human subjects are likely
to encounter in urban environments.
It has previously been reported that oral exposure to
OVA in the drinking water of experimental mice signifi-
cantly decreased the airways hyperreactivity to metha-
choline and the production of Th2 cytokines such as
IL-5 and IL-13 [43]. Our research obtained similar
r e s u l t st ot h i sp r e v i o u ss t u d ys i n c et h eP e n ho fe x p e r i -
mental mice fed with CRA was significantly lower than
that of PBS fed mice. This indicated that the allergen
fed mice were in a superior state of respiratory health as
a result of the prior, gastric exposure to the putative
antigen(s).
As mentioned previously, other research groups, using
isolated allergens have been able to induce significant
declines in Th2 cytokines following antigen tolerization.
Interestingly, we saw no differences in any of the cyto-
kines and chemokines traditionally measured in allergic
pulmonary inflammation. We therefore had to seek
other explanations for the improved respiratory health
we observed in our allergen tolerized mice. Other
groups have shown decreases in inflammatory cell infil-
trate following oral allergen desensitization [44,45]. In
our studies we observed significantly diminished eosino-
phil recruitment to the lung airspaces with no differ-
ences in the BAL levels of other inflammatory cells.
However, circulating blood eosinophils did not differ
between the experimental groups. That an equivalent
number of eosinophils were recruited into the blood in
the CRA-fed and PBS-fed animals is not surprising con-
sidering that BAL and LH levels of chemotactic agents
for these cells were equivalent between groups. This
suggests that the mechanism for decreased eosinophil
Figure 5 Antigen specificity in oral tolerance. Penh in response to 50 mg/mL of methacholine (A), bronchoalveolar lavage eosinophils (B) and
EPO activity (C) in OVA and PBS fed, CRA immunized and challenged mice. Each value is the mean ± SEM for n = 8. None of these parameters
were statistically different from each other.
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Page 7 of 11Table 1 Parameters measured in CRA fed and PBS fed mice 4 hours after final challenge. BAL and LH cytokines
assessed by sandwich ELISA and given in pg/mL
BAL LH Other
CRA-Fed PBS-Fed p CRA-Fed PBS-Fed p CRA-Fed PBS-Fed p
Eotax-1 77.86 ± 7.76 96.3 ± 7.41 0.09 7870 ± 2287 6496 ± 983.8 0.58 Tot.IgG 4.39 ± 0.77 3.25 ± 0.42 0.21
Eotax-2 173.3 ± 40.6 214.3 ± 47.9 0.54 8500 ± 1243 8340 ± 1651 0.94 Tot. IgE 45.21 ± 5.47 54.05 ± 8.92 0.41
IFN-g 45.67 ± 8.3 59.95 ± 14.8 0.41 2951 ± 297.8 2981 ± 275.8 0.94 Mucus 0.34 ± 0.12 0.54 ± 0.19 0.52
RANTES 34.34 ± 3.48 41.96 ± 3.38 0.12 1461 ± 216.7 1341 ± 198.8 0.69 BAL N 6.8E5 ± 7.7E4 6.3E5 ± 7.7E4 0.63
MIP-2 69.06 ± 4.58 72.27 ± 6.13 0.42 4739 ± 650.7 4706 ± 656.8 0.97 BAL M 1.3E5 ± 1.4E4 1.1E5 ± 1.6E4 0.41
KC 816.7 ± 142.9 813.6 ± 89.40 0.98 11814 ± 2262 10698 ± 1750 0.70 BAL L 1.3E4 ± 2.5E3 1.8E4 ± 4.5E3 0.35
IL-4 86.20 ± 8.04 91.96 ± 9.90 0.65 3740 ± 612.6 3778 ± 629.7 0.97 MPO 1.43 ± 0.12 1.48 ± 0.11 0.74
IL-5 17.19 ± 2.18 17.18 ± 2.18 0.99 1992 ± 109.9 2042 ± 143.4 0.79
IL-13 76.64 ± 6.83 91.34 ± 9.04 0.20 3859 ± 510.9 3916 ± 492.0 0.94
IL-17 80.83 ± 13.56 103.4 ± 16.96 0.30 1991 ± 306.9 2094 ± 318.0 0.82
TNF 431.1 ± 51.99 532.3 ± 67.78 0.24 1483 ± 115.3 1584 ± 81.05 0.48
IL-12 116.8 ± 30.29 101.8 ± 25.72 0.71 4639 ± 795.6 4654 ± 825.2 0.99
Total IgG and IgE given in ng/mL. Mucus reported as area of PAS staining following color deconvolution and quantitation by ImageJ freeware. BAL cells
represented as absolute cells per 2 mL sample. MPO reported as sample absorbance minus blank absorbance. All values are the mean ± SEM for n = 18.
Figure 6 Lung histology. Representative lung histology sections from CRA-fed (A) and PBS-fed (B), CRA immunized and challenged mice.
Sections are stained with H+E and PAS for mucus and magnified 10×. Quantitation of PAS staining area in CRA-fed and PBS-fed mice (C). Each
value is the mean ± SEM for n = 18.
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level of organ itself, potentially during adhesion/transmi-
gration. In addition EPO activity was also significantly
decreased in the CRA fed mice. Taken together, these
data suggest that the recruitment of eosinophils has
been inhibited to both the bronchoalveolar space and
the lung parenchyma as a whole.
Although the numbers of eosinophils in the lung were
decreased in the CRA fed mice, the levels of chemotac-
tic agents were not significantly different between the
two groups. Eotaxin 1 and 2 are as their name suggests
potent chemo attractants for eosinophils yet their con-
centrations were not significantly decreased in the CRA
fed groups [46,47]. IL-4 and IL-5 are also known eosino-
phil chemotaxins and activators, but the levels of these
cytokines were equivalent between the experimental
groups [48,49]. In addition, IL-13 which has been identi-
fied as necessary for the entrance of eosinophils into the
lung did not differ between the groups [50,51].
Having exhausted the traditional mediators of eosinophil
recruitment we decided to probe IL-10 levels. This cyto-
kine has been shown to inhibit the recruitment of eosino-
phils and alternately improve or aggravate airways
hyperreactivity [38,39,52]. IL-10 levels were significantly
elevated in the lung homogenate supernatant of the CRA
fed mice with the means differing by approximately 1000
pg/mL. This represents a 20% increase in IL-10 produc-
tion in the allergen fed mice. Whether this is a biologically
significant difference is uncertain. IL-10 is known promote
the development of oral tolerance, but the elevated levels
seen after the final challenge are not directly related to the
tolerization period which took place 24 days prior to the
final challenge [53,54]. This supposition is supported in
that the OVA tolerized mice did not differ in lung homo-
genate IL-10 levels as would be expected if a gastric toler-
izing event was responsible for this late cytokine
production (data not shown). Thus it seems likely that the
post challenge increase in IL-10 is a separate event related
to the pulmonary allergen exposure. Interestingly, the
secretion of this immunomodulatory cytokine seems lim-
ited to the pulmonary environment as serum levels of IL-
10 were below detection limit.
In conclusion, oral exposure to cockroach allergen
prior to pulmonary sensitization and challenge leads to
significantly improved respiratory health in experimental
mice. This improvement is due to reduced eosinophil
recruitment into the air spaces and lung parenchyma.
The inhibition of eosinophil recruitment may be related
to increased production of IL-10 in the lung. Finally,
this research suggests that oral tolerization to a complex
environmental allergen is a viable option for desensitiza-
tion in allergic airways disease.
Figure 7 Lung homogenate IL-10. Oral tolerance increases pulmonary levels of IL-10. IL-10 was measured in the lung homogenate supernatant
in CRA fed and PBS fed mice 4 hours after final CRA challenge. Cytokine concentration was assessed by sandwich ELISA with control lung
homogenate supernatant background removed. Each value is the mean ± SEM for n = 18. * = p < 0.05 comparing CRA fed to PBS fed mice.
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This research indicates that oral tolerization is a valid
means to reduce pulmonary inflammation in a mouse
model of allergic asthma. Oral tolerization presents an
attractive therapeutic option for human asthmatics in
that it addresses the primary cause of allergic asthma
exacerbations rather than simply blunting the symp-
toms. In addition oral tolerization offers significant
advantages over other desensitization procedures (epi-
dermal injections) in that there is a much lower risk of
anaphylaxis and treatments may be self-administered
after an initial observation period.
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